AU8281398A - Methods of inhibiting or enhancing the tgfbeta-smad signaling pathway - Google Patents

Methods of inhibiting or enhancing the tgfbeta-smad signaling pathway

Info

Publication number
AU8281398A
AU8281398A AU82813/98A AU8281398A AU8281398A AU 8281398 A AU8281398 A AU 8281398A AU 82813/98 A AU82813/98 A AU 82813/98A AU 8281398 A AU8281398 A AU 8281398A AU 8281398 A AU8281398 A AU 8281398A
Authority
AU
Australia
Prior art keywords
tgfbeta
inhibiting
enhancing
methods
signaling pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU82813/98A
Inventor
Joan Massague
Nikola Pavletich
Yigong Shi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research
Publication of AU8281398A publication Critical patent/AU8281398A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
AU82813/98A 1997-07-01 1998-07-01 Methods of inhibiting or enhancing the tgfbeta-smad signaling pathway Abandoned AU8281398A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5277497P 1997-07-01 1997-07-01
US60052774 1997-07-01
US6511397P 1997-11-12 1997-11-12
US60065113 1997-11-12
PCT/US1998/013721 WO1999001765A1 (en) 1997-07-01 1998-07-01 METHODS OF INHIBITING OR ENHANCING THE TGFβ-SMAD SIGNALING PATHWAY

Publications (1)

Publication Number Publication Date
AU8281398A true AU8281398A (en) 1999-01-25

Family

ID=26731059

Family Applications (1)

Application Number Title Priority Date Filing Date
AU82813/98A Abandoned AU8281398A (en) 1997-07-01 1998-07-01 Methods of inhibiting or enhancing the tgfbeta-smad signaling pathway

Country Status (2)

Country Link
AU (1) AU8281398A (en)
WO (1) WO1999001765A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042280A2 (en) * 1999-12-09 2001-06-14 Children's Medical Center Corporation Short peptides from the b4 and b5 regions of protein kinases which selectively modulate protein activity
US7358056B1 (en) 1999-08-30 2008-04-15 Signal Pharmaceuticals Methods for modulating signal transduction mediated by TGF-β and related proteins

Also Published As

Publication number Publication date
WO1999001765A1 (en) 1999-01-14

Similar Documents

Publication Publication Date Title
HUP9800581A3 (en) Modified primers
AU8547198A (en) Pyridyl- and pyrimidyl-heterocyclic compounds inhibiting oxido squalene-cyclase
AU5251799A (en) Prevention of endometriosis signs or symptoms
AU2098799A (en) Method of inhibiting interleukin-12 signaling
AU2968599A (en) Alarm
AU6827898A (en) Detergent-package combination
GB9926537D0 (en) Compounds on the basis of polyalkyl-1-oxa diazaspirodecane compounds
AU9066598A (en) Substituted 4-benzoyl-pyrazoles
EP1144305A4 (en) NOVEL sPLA 2 INHIBITORS
GB9816214D0 (en) Deactivator
AU5446499A (en) Apoptosis inducing agents
AU8095598A (en) Hair-drier or the like
AU5533898A (en) Cork-based protected stopper
AUPO371096A0 (en) Corrosion inhibiting composition
AU6090898A (en) Substituted 4-benzoyl-pyrazoles
AU8281398A (en) Methods of inhibiting or enhancing the tgfbeta-smad signaling pathway
AU3113600A (en) Anticancer agents based on prevention of protein prenylation
AU6442598A (en) Visual signaling device
AU8408798A (en) Methods and compositions for inhibiting the proinflammatory response
IL132439A0 (en) Substituted 2-benzoylcyclohexane-1 3-diones
AU7530198A (en) Substituted 4-benzoyl-pyrazoles
AU7212698A (en) Substituted aryluracils
GB2325866B (en) Cracker
AU4946697A (en) Dihydrobenzoanthracenone, -pyrimidinone or dihydronaphtoquinolinone
ZA979045B (en) Derivates of pentaerythrits.

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase